http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 14 Aug 2026 21:33:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Yarrow+Bioscience%2C+Inc.++++++++++++++++Filed+by%3A+ADAR1+Capital+Management%2C+LLC/26933329.html si-local-file:///var/storage/secattach/20260814/26933329.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Yarrow+Bioscience%2C+Inc.++++++++++++++++Filed+by%3A+ADAR1+Capital+Management%2C+LLC/26933329.html Fri, 14 Aug 2026 21:33:00 -0400 O.37307441 YARW http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Yarrow+Bioscience%2C+Inc.++++++++++++++++Filed+by%3A+ADAR1+Capital+Management%2C+LLC/26933329.html si-local-file:///var/storage/secattach/20260814/26933329.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Yarrow+Bioscience%2C+Inc.++++++++++++++++Filed+by%3A+ADAR1+Capital+Management%2C+LLC/26933329.html Fri, 14 Aug 2026 21:33:00 -0400 O.37307441 YARW http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Yarrow+Bioscience%2C+Inc.++++++++++++++++Filed+by%3A+venBio+Global+Strategic+Fund+V%2C+L.P./26931912.html si-local-file:///var/storage/secattach/20260814/26931912.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Yarrow+Bioscience%2C+Inc.++++++++++++++++Filed+by%3A+venBio+Global+Strategic+Fund+V%2C+L.P./26931912.html Fri, 14 Aug 2026 16:41:00 -0400 O.37307441 YARW http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Yarrow+Bioscience%2C+Inc.++++++++++++++++Filed+by%3A+venBio+Global+Strategic+Fund+V%2C+L.P./26931912.html si-local-file:///var/storage/secattach/20260814/26931912.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Yarrow+Bioscience%2C+Inc.++++++++++++++++Filed+by%3A+venBio+Global+Strategic+Fund+V%2C+L.P./26931912.html Fri, 14 Aug 2026 16:41:00 -0400 O.37307441 YARW http://www.streetinsider.com/SEC+Filings/Form++POS+AM+++++Yarrow+Bioscience%2C+Inc.++++++++++++++/26923892.html si-local-file:///var/storage/secattach/20260814/26923892.html http://www.streetinsider.com/SEC+Filings/Form++POS+AM+++++Yarrow+Bioscience%2C+Inc.++++++++++++++/26923892.html Fri, 14 Aug 2026 06:05:00 -0400 O.37307441 YARW http://www.streetinsider.com/SEC+Filings/Form++POS+AM+++++Yarrow+Bioscience%2C+Inc.++++++++++++++/26923892.html si-local-file:///var/storage/secattach/20260814/26923892.html http://www.streetinsider.com/SEC+Filings/Form++POS+AM+++++Yarrow+Bioscience%2C+Inc.++++++++++++++/26923892.html Fri, 14 Aug 2026 06:05:00 -0400 O.37307441 YARW http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++Yarrow+Bioscience%2C+Inc.+++For%3A+Jul+24/26921306.html si-local-file:///var/storage/secattach/20260813/26921306.html http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++Yarrow+Bioscience%2C+Inc.+++For%3A+Jul+24/26921306.html Thu, 13 Aug 2026 16:15:00 -0400 O.37307441 YARW http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++Yarrow+Bioscience%2C+Inc.+++For%3A+Jul+24/26921306.html si-local-file:///var/storage/secattach/20260813/26921306.html http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++Yarrow+Bioscience%2C+Inc.+++For%3A+Jul+24/26921306.html Thu, 13 Aug 2026 16:15:00 -0400 O.37307441 YARW http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Yarrow+Bioscience%2C+Inc.+++For%3A+Jun+30/26920627.html si-local-file:///var/storage/secattach/20260813/26920627.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Yarrow+Bioscience%2C+Inc.+++For%3A+Jun+30/26920627.html Thu, 13 Aug 2026 16:04:00 -0400 O.37307441 YARW http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Yarrow+Bioscience%2C+Inc.+++For%3A+Jun+30/26920627.html si-local-file:///var/storage/secattach/20260813/26920627.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Yarrow+Bioscience%2C+Inc.+++For%3A+Jun+30/26920627.html Thu, 13 Aug 2026 16:04:00 -0400 O.37307441 YARW http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Yarrow+Bioscience%2C+Inc.++++++++++++++++Filed+by%3A+Zhang+Xiaofan/26917972.html si-local-file:///var/storage/secattach/20260813/26917972.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Yarrow+Bioscience%2C+Inc.++++++++++++++++Filed+by%3A+Zhang+Xiaofan/26917972.html Thu, 13 Aug 2026 10:01:00 -0400 O.37307441 YARW http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Yarrow+Bioscience%2C+Inc.++++++++++++++++Filed+by%3A+Zhang+Xiaofan/26917972.html si-local-file:///var/storage/secattach/20260813/26917972.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Yarrow+Bioscience%2C+Inc.++++++++++++++++Filed+by%3A+Zhang+Xiaofan/26917972.html Thu, 13 Aug 2026 10:01:00 -0400 O.37307441 YARW http://www.streetinsider.com/Press+Releases/Yarrow+Bioscience+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26916189.html <p class="bwalignc"> <i>Enrollment ongoing in Phase 2a/2b trial evaluating YB-101, a potential first-in-class anti-TSHR antibody, in patients with Graves’ disease (with or without TED); Phase 2a topline results expected in the second half of 2027</i> </p><p class="bwalignc"> <i>Closed previously announced private financings totaling $200 million; expected to fund operations into 2028</i> </p><p class="bwalignc"> <i>Completed reverse merger with VYNE Therapeutics and commenced trading on Nasdaq under the ticker symbol “YARW”</i> </p> <p> NEW HAVEN, Conn.--(BUSINESS WIRE)-- Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced financial results for the second quarter http://www.streetinsider.com/Press+Releases/Yarrow+Bioscience+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26916189.html Thu, 13 Aug 2026 07:00:00 -0400 A.06822034 A.50200171 A.50213959 A.50216428 A.50216777 O.00478238 O.02836754 O.20026344 O.37307441 O.54516537 O.55864350 YARW http://www.streetinsider.com/Press+Releases/Yarrow+Bioscience+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26916189.html <p class="bwalignc"> <i>Enrollment ongoing in Phase 2a/2b trial evaluating YB-101, a potential first-in-class anti-TSHR antibody, in patients with Graves’ disease (with or without TED); Phase 2a topline results expected in the second half of 2027</i> </p><p class="bwalignc"> <i>Closed previously announced private financings totaling $200 million; expected to fund operations into 2028</i> </p><p class="bwalignc"> <i>Completed reverse merger with VYNE Therapeutics and commenced trading on Nasdaq under the ticker symbol “YARW”</i> </p> <p> NEW HAVEN, Conn.--(BUSINESS WIRE)-- Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced financial results for the second quarter http://www.streetinsider.com/Press+Releases/Yarrow+Bioscience+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26916189.html Thu, 13 Aug 2026 07:00:00 -0400 A.06822034 A.50200171 A.50213959 A.50216428 A.50216777 O.00478238 O.02836754 O.20026344 O.37307441 O.54516537 O.55864350 YARW http://www.streetinsider.com/Press+Releases/Yarrow+Bioscience+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26916189.html <p class="bwalignc"> <i>Enrollment ongoing in Phase 2a/2b trial evaluating YB-101, a potential first-in-class anti-TSHR antibody, in patients with Graves’ disease (with or without TED); Phase 2a topline results expected in the second half of 2027</i> </p><p class="bwalignc"> <i>Closed previously announced private financings totaling $200 million; expected to fund operations into 2028</i> </p><p class="bwalignc"> <i>Completed reverse merger with VYNE Therapeutics and commenced trading on Nasdaq under the ticker symbol “YARW”</i> </p> <p> NEW HAVEN, Conn.--(BUSINESS WIRE)-- Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced financial results for the second quarter http://www.streetinsider.com/Press+Releases/Yarrow+Bioscience+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26916189.html Thu, 13 Aug 2026 07:00:00 -0400 A.06822034 A.50200171 A.50213959 A.50216428 A.50216777 O.00478238 O.02836754 O.20026344 O.37307441 O.54516537 O.55864350 YARW http://www.streetinsider.com/Press+Releases/Yarrow+Bioscience+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26916189.html <p class="bwalignc"> <i>Enrollment ongoing in Phase 2a/2b trial evaluating YB-101, a potential first-in-class anti-TSHR antibody, in patients with Graves’ disease (with or without TED); Phase 2a topline results expected in the second half of 2027</i> </p><p class="bwalignc"> <i>Closed previously announced private financings totaling $200 million; expected to fund operations into 2028</i> </p><p class="bwalignc"> <i>Completed reverse merger with VYNE Therapeutics and commenced trading on Nasdaq under the ticker symbol “YARW”</i> </p> <p> NEW HAVEN, Conn.--(BUSINESS WIRE)-- Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced financial results for the second quarter http://www.streetinsider.com/Press+Releases/Yarrow+Bioscience+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26916189.html Thu, 13 Aug 2026 07:00:00 -0400 A.06822034 A.50200171 A.50213959 A.50216428 A.50216777 O.00478238 O.02836754 O.20026344 O.37307441 O.54516537 O.55864350 YARW http://www.streetinsider.com/Press+Releases/Yarrow+Bioscience+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26916189.html <p class="bwalignc"> <i>Enrollment ongoing in Phase 2a/2b trial evaluating YB-101, a potential first-in-class anti-TSHR antibody, in patients with Graves’ disease (with or without TED); Phase 2a topline results expected in the second half of 2027</i> </p><p class="bwalignc"> <i>Closed previously announced private financings totaling $200 million; expected to fund operations into 2028</i> </p><p class="bwalignc"> <i>Completed reverse merger with VYNE Therapeutics and commenced trading on Nasdaq under the ticker symbol “YARW”</i> </p> <p> NEW HAVEN, Conn.--(BUSINESS WIRE)-- Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced financial results for the second quarter http://www.streetinsider.com/Press+Releases/Yarrow+Bioscience+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26916189.html Thu, 13 Aug 2026 07:00:00 -0400 A.06822034 A.50200171 A.50213959 A.50216428 A.50216777 O.00478238 O.02836754 O.20026344 O.37307441 O.54516537 O.55864350 YARW http://www.streetinsider.com/Press+Releases/Yarrow+Bioscience+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26916189.html <p class="bwalignc"> <i>Enrollment ongoing in Phase 2a/2b trial evaluating YB-101, a potential first-in-class anti-TSHR antibody, in patients with Graves’ disease (with or without TED); Phase 2a topline results expected in the second half of 2027</i> </p><p class="bwalignc"> <i>Closed previously announced private financings totaling $200 million; expected to fund operations into 2028</i> </p><p class="bwalignc"> <i>Completed reverse merger with VYNE Therapeutics and commenced trading on Nasdaq under the ticker symbol “YARW”</i> </p> <p> NEW HAVEN, Conn.--(BUSINESS WIRE)-- Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced financial results for the second quarter http://www.streetinsider.com/Press+Releases/Yarrow+Bioscience+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26916189.html Thu, 13 Aug 2026 07:00:00 -0400 A.06822034 A.50200171 A.50213959 A.50216428 A.50216777 O.00478238 O.02836754 O.20026344 O.37307441 O.54516537 O.55864350 YARW http://www.streetinsider.com/Press+Releases/Yarrow+Bioscience+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26916189.html <p class="bwalignc"> <i>Enrollment ongoing in Phase 2a/2b trial evaluating YB-101, a potential first-in-class anti-TSHR antibody, in patients with Graves’ disease (with or without TED); Phase 2a topline results expected in the second half of 2027</i> </p><p class="bwalignc"> <i>Closed previously announced private financings totaling $200 million; expected to fund operations into 2028</i> </p><p class="bwalignc"> <i>Completed reverse merger with VYNE Therapeutics and commenced trading on Nasdaq under the ticker symbol “YARW”</i> </p> <p> NEW HAVEN, Conn.--(BUSINESS WIRE)-- Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced financial results for the second quarter http://www.streetinsider.com/Press+Releases/Yarrow+Bioscience+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26916189.html Thu, 13 Aug 2026 07:00:00 -0400 A.06822034 A.50200171 A.50213959 A.50216428 A.50216777 O.00478238 O.02836754 O.20026344 O.37307441 O.54516537 O.55864350 YARW http://www.streetinsider.com/Press+Releases/Yarrow+Bioscience+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26916189.html <p class="bwalignc"> <i>Enrollment ongoing in Phase 2a/2b trial evaluating YB-101, a potential first-in-class anti-TSHR antibody, in patients with Graves’ disease (with or without TED); Phase 2a topline results expected in the second half of 2027</i> </p><p class="bwalignc"> <i>Closed previously announced private financings totaling $200 million; expected to fund operations into 2028</i> </p><p class="bwalignc"> <i>Completed reverse merger with VYNE Therapeutics and commenced trading on Nasdaq under the ticker symbol “YARW”</i> </p> <p> NEW HAVEN, Conn.--(BUSINESS WIRE)-- Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced financial results for the second quarter http://www.streetinsider.com/Press+Releases/Yarrow+Bioscience+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26916189.html Thu, 13 Aug 2026 07:00:00 -0400 A.06822034 A.50200171 A.50213959 A.50216428 A.50216777 O.00478238 O.02836754 O.20026344 O.37307441 O.54516537 O.55864350 YARW http://www.streetinsider.com/Press+Releases/Yarrow+Bioscience+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26916189.html <p class="bwalignc"> <i>Enrollment ongoing in Phase 2a/2b trial evaluating YB-101, a potential first-in-class anti-TSHR antibody, in patients with Graves’ disease (with or without TED); Phase 2a topline results expected in the second half of 2027</i> </p><p class="bwalignc"> <i>Closed previously announced private financings totaling $200 million; expected to fund operations into 2028</i> </p><p class="bwalignc"> <i>Completed reverse merger with VYNE Therapeutics and commenced trading on Nasdaq under the ticker symbol “YARW”</i> </p> <p> NEW HAVEN, Conn.--(BUSINESS WIRE)-- Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced financial results for the second quarter http://www.streetinsider.com/Press+Releases/Yarrow+Bioscience+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26916189.html Thu, 13 Aug 2026 07:00:00 -0400 A.06822034 A.50200171 A.50213959 A.50216428 A.50216777 O.00478238 O.02836754 O.20026344 O.37307441 O.54516537 O.55864350 YARW http://www.streetinsider.com/Press+Releases/Yarrow+Bioscience+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26916189.html <p class="bwalignc"> <i>Enrollment ongoing in Phase 2a/2b trial evaluating YB-101, a potential first-in-class anti-TSHR antibody, in patients with Graves’ disease (with or without TED); Phase 2a topline results expected in the second half of 2027</i> </p><p class="bwalignc"> <i>Closed previously announced private financings totaling $200 million; expected to fund operations into 2028</i> </p><p class="bwalignc"> <i>Completed reverse merger with VYNE Therapeutics and commenced trading on Nasdaq under the ticker symbol “YARW”</i> </p> <p> NEW HAVEN, Conn.--(BUSINESS WIRE)-- Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced financial results for the second quarter http://www.streetinsider.com/Press+Releases/Yarrow+Bioscience+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26916189.html Thu, 13 Aug 2026 07:00:00 -0400 A.06822034 A.50200171 A.50213959 A.50216428 A.50216777 O.00478238 O.02836754 O.20026344 O.37307441 O.54516537 O.55864350 YARW http://www.streetinsider.com/Press+Releases/Yarrow+Bioscience+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26916189.html <p class="bwalignc"> <i>Enrollment ongoing in Phase 2a/2b trial evaluating YB-101, a potential first-in-class anti-TSHR antibody, in patients with Graves’ disease (with or without TED); Phase 2a topline results expected in the second half of 2027</i> </p><p class="bwalignc"> <i>Closed previously announced private financings totaling $200 million; expected to fund operations into 2028</i> </p><p class="bwalignc"> <i>Completed reverse merger with VYNE Therapeutics and commenced trading on Nasdaq under the ticker symbol “YARW”</i> </p> <p> NEW HAVEN, Conn.--(BUSINESS WIRE)-- Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced financial results for the second quarter http://www.streetinsider.com/Press+Releases/Yarrow+Bioscience+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26916189.html Thu, 13 Aug 2026 07:00:00 -0400 A.06822034 A.50200171 A.50213959 A.50216428 A.50216777 O.00478238 O.02836754 O.20026344 O.37307441 O.54516537 O.55864350 YARW http://www.streetinsider.com/Press+Releases/Yarrow+Bioscience+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26916189.html <p class="bwalignc"> <i>Enrollment ongoing in Phase 2a/2b trial evaluating YB-101, a potential first-in-class anti-TSHR antibody, in patients with Graves’ disease (with or without TED); Phase 2a topline results expected in the second half of 2027</i> </p><p class="bwalignc"> <i>Closed previously announced private financings totaling $200 million; expected to fund operations into 2028</i> </p><p class="bwalignc"> <i>Completed reverse merger with VYNE Therapeutics and commenced trading on Nasdaq under the ticker symbol “YARW”</i> </p> <p> NEW HAVEN, Conn.--(BUSINESS WIRE)-- Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced financial results for the second quarter http://www.streetinsider.com/Press+Releases/Yarrow+Bioscience+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26916189.html Thu, 13 Aug 2026 07:00:00 -0400 A.06822034 A.50200171 A.50213959 A.50216428 A.50216777 O.00478238 O.02836754 O.20026344 O.37307441 O.54516537 O.55864350 YARW http://www.streetinsider.com/Business+Wire/Yarrow+Bioscience+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26916189.html <p class="bwalignc"> <i>Enrollment ongoing in Phase 2a/2b trial evaluating YB-101, a potential first-in-class anti-TSHR antibody, in patients with Graves’ disease (with or without TED); Phase 2a topline results expected in the second half of 2027</i> </p><p class="bwalignc"> <i>Closed previously announced private financings totaling $200 million; expected to fund operations into 2028</i> </p><p class="bwalignc"> <i>Completed reverse merger with VYNE Therapeutics and commenced trading on Nasdaq under the ticker symbol “YARW”</i> </p> <p> NEW HAVEN, Conn.--(BUSINESS WIRE)-- Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced financial results for the second quarter http://www.streetinsider.com/Business+Wire/Yarrow+Bioscience+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26916189.html Thu, 13 Aug 2026 07:00:00 -0400 A.06822034 A.50200171 A.50213959 A.50216428 A.50216777 O.00478238 O.02836754 O.20026344 O.37307441 O.54516537 O.55864350 YARW